JP2022526495A5 - - Google Patents

Info

Publication number
JP2022526495A5
JP2022526495A5 JP2021556420A JP2021556420A JP2022526495A5 JP 2022526495 A5 JP2022526495 A5 JP 2022526495A5 JP 2021556420 A JP2021556420 A JP 2021556420A JP 2021556420 A JP2021556420 A JP 2021556420A JP 2022526495 A5 JP2022526495 A5 JP 2022526495A5
Authority
JP
Japan
Prior art keywords
rifamycin
mucolytic agent
pharmaceutical composition
use according
rifaximin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021556420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526495A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/023396 external-priority patent/WO2020191076A1/en
Publication of JP2022526495A publication Critical patent/JP2022526495A/ja
Publication of JP2022526495A5 publication Critical patent/JP2022526495A5/ja
Pending legal-status Critical Current

Links

JP2021556420A 2019-03-18 2020-03-18 胃腸疾患および障害を治療するための組成物およびその方法 Pending JP2022526495A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819986P 2019-03-18 2019-03-18
US62/819,986 2019-03-18
PCT/US2020/023396 WO2020191076A1 (en) 2019-03-18 2020-03-18 Compositions and methods to treat gastrointestinal diseases and disorders

Publications (2)

Publication Number Publication Date
JP2022526495A JP2022526495A (ja) 2022-05-25
JP2022526495A5 true JP2022526495A5 (https=) 2023-03-14

Family

ID=72520533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556420A Pending JP2022526495A (ja) 2019-03-18 2020-03-18 胃腸疾患および障害を治療するための組成物およびその方法

Country Status (7)

Country Link
US (1) US20230038019A1 (https=)
EP (1) EP3941461A4 (https=)
JP (1) JP2022526495A (https=)
CN (1) CN113645968A (https=)
AU (2) AU2020240069B2 (https=)
CA (2) CA3132400A1 (https=)
WO (1) WO2020191076A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023205650A1 (en) * 2022-04-20 2023-10-26 Cedars-Sinai Medical Center Methods of diagnosing ibs-d and selection of ibs-d treatment
US20250275950A1 (en) * 2022-05-19 2025-09-04 Cedars-Sinai Medical Center Rifaximin and n-acetyl cysteine formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1235529A (en) * 1968-12-02 1971-06-16 Calbiochem Composition for mucolysis
TWI236905B (en) * 1997-10-28 2005-08-01 Jens Ponikau Pharmaceutical composition for treating and preventing inflammation of mucosal tissue
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20060264409A1 (en) * 2004-01-20 2006-11-23 Harty Richard F Compositions and methods of treatment for inflammatory diseases
WO2005118860A2 (en) * 2004-04-09 2005-12-15 General Hospital Corporation Compositions and methods related to an intestinal inflammation and uses therefor
CN101039701A (zh) * 2004-08-26 2007-09-19 尼古拉斯皮拉马尔印度有限公司 含有生物可裂解二硫化物连接物的前药和共药
US20120283411A9 (en) * 2006-06-29 2012-11-08 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0823472D0 (en) * 2008-12-23 2009-01-28 Photocure Asa Product
JP2013518895A (ja) * 2010-02-03 2013-05-23 マイクロビオン コーポレーション 細菌バイオフィルムの処置および他の使用をはじめとする、生体医学的使用のための消毒薬としてのビスマス−チオール
MX2015002210A (es) * 2012-08-29 2015-05-08 Salix Pharmaceuticals Inc Composiciones laxantes y metodos para tratar estreñimiento y enfermedades y condiciones gastrointestinales relacionadas.
WO2014036445A2 (en) * 2012-08-31 2014-03-06 Johnson Michael R Novel mucolytic agents
WO2014070769A1 (en) * 2012-10-29 2014-05-08 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
ITMI20130874A1 (it) * 2013-05-29 2014-11-30 Zambon Spa Compresse deglutibili di n-acetilcisteina
US20160158262A1 (en) * 2013-07-26 2016-06-09 Cedars-Sinai Medical Center Methods of treating irritable bowel syndrome
WO2016003536A1 (en) * 2014-06-30 2016-01-07 Salix Pharmaceuticals, Inc. Methods for retreating irritable bowel syndrome (ibs)
SG11201700621XA (en) * 2014-07-25 2017-02-27 Agency Science Tech & Res Antibiotic compositions for treating bacterial infections
DK3288554T3 (da) * 2015-04-30 2022-11-14 Probiotical Spa Anvendelse af antibiotika med specifikke terapeutiske aktiviteter kombineret med samtidig anvendelse af lactobacilli og/eller bifidobakterier med en ikke-overførbar antibiotisk resistens med den samme terapeutiske indikation
KR20190116320A (ko) * 2017-02-07 2019-10-14 에스티씨. 유엔엠 오래 지속되는 자가 포식 유도를 위한 동위 원소 강화 암브록솔

Similar Documents

Publication Publication Date Title
CN104958282B (zh) 他喷他多组合物
JP2022537551A5 (https=)
BR112012028035A2 (pt) forma de dosagem e formulação de liberação imediata, e, uso das mesmas
JP2022517433A5 (https=)
CN107260695A (zh) 硝唑尼特的控制释放药物剂型
JP2018507243A5 (https=)
JP2009501801A5 (https=)
JP2021512149A5 (https=)
WO2012173581A4 (en) Thiocolchicoside, etodolac and famotidine combinations
ME02474B (me) Terapijski režimi
JP2021509395A5 (https=)
JP2022526495A5 (https=)
JP2019518022A5 (https=)
JP2018531273A5 (https=)
JP2019218379A5 (https=)
US20180221315A1 (en) Combination therapy using acamprosate and d-cycloserine
JP2024517085A5 (https=)
JP2016505050A5 (https=)
US10188610B2 (en) Prolonged-release diphenidol composition
JP2012505830A5 (https=)
JP2025508098A5 (https=)
JP2022177119A5 (https=)
ES2286716T3 (es) Composicion farmaceutica de liberacion controlada y proceso para preparar la misma.
JP2019522030A5 (https=)
JP2021530568A5 (https=)